A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: Effects of tumor burden and antigen expression

Journal of Clinical Oncology

Volumn 8, Issue 5, 1990, Pages 792-803

  Scheinberg, David A ^a   Straus, David J ^a   Yeh, Samuel D ^a   Divgi, Chaitanya ^a   Garin Chesa, Pilar ^a   Graham, Martin ^a   Pentlow, Keith ^a   Coit, Daniel ^a   Oettgen, Herbert F ^a   Old, Lloyd J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OKB7; RADIOISOTOPE; UNCLASSIFIED DRUG;

AGE; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIODINATION;

ADULT; AGED; ANIMAL; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; DRUG EVALUATION; FEMALE; HALF-LIFE; HUMAN; IODINE RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; MALE; METABOLIC CLEARANCE RATE; MICE; MIDDLE AGE; RADIOMETRY; SUPPORT, NON-U.S. GOV'T; TISSUE DISTRIBUTION;

EID: 0025216138     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1990.8.5.792     Document Type: Article

References (42)

1. Houghton AN, Scheinberg DA: Monoclonal antibodies: Potential applications to the treatment of cancer. Semin Oncol 13:165-179, 1986
2. Scheinberg DA, Houghton AN: Current status of antitumor therapy with monoclonal antibodies. Oncology 2:31-40, 1987
3. Miller RA, Levy R: Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 2:226-230, 1981
4. Ritz J, Pesando JM, Sallan SE, et al: Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood 58:141-152, 1981
5. Foon KA, Schroff RW, Bunn PA, et al: Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 64:1085-1093, 1984
6. Waldmann TA, Goldman CK, Bongiovanni KF, et al: Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-tac, a monoclonal antibody to the receptor for interleukin-2. Blood 72:1805-1816, 1988
7. Dillman RO, Shawler DL, Dillman DB, et al: Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphomas with T101 monoclonal antibody. J Clin Oncol 2:881-891, 1984
8. DeNardo SJ, DeNardo GL, O'Grady LF, et al: Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 lym-1 monoclonal antibody. Antibodies, Immunoconjugates Radiopharmaceut 1:17-27, 1988
9. 131I-labeled monoclonal antibody: An Illinois Cancer Council study. J Clin Oncol 5:562-573, 1987
10. DeNardo SJ, O'Grady LF, DeNardo GC, et al: Radioimmunotherapy of lymphoproliferative disease. Blood 72:241a, 1988 (abstr)
11. Dyer MJS, Hale G, Hayhoe FGJ, et al: Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 73:1431-1439, 1989
12. Hale G, Dyer MJS, Clark MR, et al: Remission induction in non-Hodgkin lymphoma with the reshaped human monoclonal antibody CAMPATH-1H. Lancet 2:1394-1399, 1988
13. Press OW, Eary JF, Badjer CC, et al: Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (Anti-CD37) antibody. J Clin Oncol, (in press, 1989)
14. Foon KA, Todd III RF: Immunologic classification of leukemia and lymphoma. Blood 68:1-31, 1986
15. Koziner B, Little C, Passe S, et al: Treatment of advanced diffuse histiocytic lymphoma: An analysis of prognostic variables. Cancer 49:1571-1586, 1982
16. Al Katib A, Koziner B, Kurland E, et al: Treatment of diffuse poorly differentiated lymphocytic lymphoma: An analysis of prognostic variables. Cancer 53:2404-2412, 1984
17. Portlock CS: "Good risk" non-Hodgkin's lymphomas: Approaches to management. Sem Hematol 20:25-34, 1983
18. Cabanillas F, Hagemeister FB, McLaughlin P, et al: Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 5:407-412, 1987
19. Press OW, Appelbaum F, Ledbetter JA, et al: Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B cell lymphomas. Blood 69:584-591, 1987
20. Meeker TC, Lowder J, Maloney DV, et al: A clinical trial of anti-idiotype therapy for B-cell malignancy. Blood 65:1349-1363, 1985
21. Brown SL, Miller RA, Horning SJ, et al: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73:651-661, 1989
22. Meeker T, Lowder J, Cleary ML, et al: Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med 312:1658-1665, 1985
23. Mittler RS, Talle MA, Carpender K, et al: Generation and characterization of monoclonal antibodies reactive with human B lymphocytes. J Immunol 131:1754-1761, 1983
24. Nemerow GR, Wolfert R, McNaughton ME, et al: Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol 55:347-351, 1985
25. Siaw MFE, Nemerow GR, Cooper NR: Biochemical and antigenic analysis of the Epstein-Barr virus/C3d receptor (CR2). J Immunol 136:4146-4151, 1986
26. Knowles II DM, Dodson LD, Raab R, et al: The application of monoclonal antibodies to the characterization and diagnosis of lymphoid neoplasms: A review of recent studies. Diag Immuno 1:142-149, 1983
27. Knowles II DM, Tolidijian B, Marboe CC, et al: Distribution of antigens defined by OKB monoclonal antibodies on benign and benign and malignant lymphoid cells and on non-lymphoid tissues. Blood 63:886-896, 1984
28. Nemerow GR, McNaughton ME, Cooper NR: Binding of monoclonal antibody to the EBV/CR2 receptor in-duces activation and differentiation of human B lymphocytes. J Immunol 135:3068-3073, 1985
29. Bohnsack JF, Cooper NR: CR2 ligands modulate human B cell activation. J Immunol 141:2569-2576, 1988
30. Snyder WS, Ford MR, Warner GG, et al: MIRD S Factors Pamphlet No. 11. Society of Nuclear Medicine Publishers, Oak Ridge, TN, 1975
31. Garin-Chesa P, Rettig WJ, Thomson PM, et al: Immunohistochemical analysis of nerve growth factor receptor expression in normal and malignant human tissues. J Histochem Cytochem 36:383-389, 1988
32. Tanimoto M, Scheinberg DA, Cordon-Cardo C, et al: Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia 3:339-348, 1989
33. Scheinberg DA, Strand M: Kinetic and catabolic considerations of monoclonal antibody targeting in erythroleukemic mice. Cancer Res 43:265-272, 1983
34. Carrasquillo JA, Mulshine JL, Bunn PA Jr, et al: Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J Nucl Med 28:281-287, 1987
35. 111In-labeled T101 monoclonal antibody. N Engl J Med 315:673-680, 1986
36. Scheinberg DA, Strand M, Gansow OA: Tumor imaging with radioactive metal chelate conjugated monoclonal antibodies. Science 215:1511-1513, 1982
37. Benhua RS, Cicale NR, Sonenberg M, et al: The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid carcinoma. Am J Roentgen 87:171-178, 1962
38. 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49:2807-2813, 1989
39. 131I-AS33 in colorectal cancer. Proc Am Soc Clin Oncol 8:106, 1989 (abstr)
40. Cohn KH, Welt S, Banner WP, et al: Localization of radioiodinated monoclonal antibody in colorectal cancer. Arch Surg 122:1425-1429, 1987
41. Letvin JL, Ritz J, Guida LJ, et al: In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: 1. Effects of anti-T11 antibodies on the circulating T cell pool. Blood 66:961-966, 1985
42. 131I-9.2.27 monoclonal antibody in human malignant melanoma. Cancer Res 49:2783-2789, 1989